Idéal Investisseur
Français English
CAC 40 :
8 157,82 pts
-0.84%


Last updated : 24/04/2026 - 17h35

Stock ARGENX SE (NL0010832176)

Sector : Pharmaceuticals & Biotechnology – Indices : EURONEXT 100, BEL ALL-SHARE

Price 666,20 €
Daily change -2,80 %
1 week -6,25 %
1 month 0,00 %
1 year +26,27 %

Last update : 24/04/2026 at 17:36:30 – Source: Euronext

Assurance vie

Market summary

As of 24/04/2026, stock ARGENX SE trades at 666,20 € , with a change of -2,80 % , and a market cap of 41 429 M€.

Open0,00 €
Previous close685,40 €
Volume83 268
Market cap41 429 M€
P/EN/A
Dividend / shareN/A
Float turnover0,00 %
MarketEuronext BRUXELLES
Eligible

Price and moving averages

Technical analysis ARGENX SE

50-day moving average677,28 €-1.64 % (below) Pivot669,4 €
Support level584,8 €-12.22 % Resistance level722,4 €+8.44 %
1-month volatility10,01 % Annualised volatility34,68 %
RSI (14d)24 Oversold Stochastic signal (14d)Neutre
ATR (14d)17,63 High volatility CMF (21d)-0,35 Moderate selling pressure
Bollinger bands (20d) Neutral OBV (21d) Neutral (OBV stable)

Analyst consensus and recommendations

Median target :
725,00 € (+8,83 %)

Sample rating :
DateAnalyst / BrokerRatingTarget
11/03 Deutsche Bank acheter 725,00 €
10/03 Bernstein surperformance 915,00 €
13/02 Goldman Sachs achat 780,00 €

Stock history and statistics

IPO dateJul 10, 2014
52-week high738,00 €52-week low568,40 €
All-time high810,00 €All-time low6,23 €
1-year volatility34,68 %Beta-0,10

Financial calendar — ARGENX SE

📅
February 26, 2026 Annual results 2025
📅
May 6, 2026 Annual General Meeting 2026
📅
May 7, 2026 Résultats Q1 2026
📅
July 23, 2026 Résultats Q2 et 1er semestre 2026
📅
October 22, 2026 Résultats Q3 2026

Recent news — ARGENX SE

The biopharmaceutical group argenx announces the presentation of new clinical data for VYVGART and its drug candidates at the annual American Academy …

Argenx announces its annual general meeting on May 6, 2026, in the Netherlands. The meeting will include the review of the 2025 financial statements a…

Argenx announces through a press release that it will present new clinical data at the American Academy of Neurology (AAN) annual conference in April …

Argenx laboratory revealed on Thursday the positive results of its phase 3 ADAPT OCULUS clinical trial evaluating Vyvgart in the treatment of ocular m…

Analyses on ARGENX SE stock

No analysis has been published on this stock yet.

Frequently asked questions about ARGENX SE stock

What does the recent price action of ARGENX SE stock show?

ARGENX SE stock is currently trading around 666,20 €, down 2,80% and down 0,06% over one week.

Is ARGENX SE stock in a support or resistance zone?

Technical levels help place the stock. Support: 584,80 €. Resistance: 722,40 €.

How should the current volatility of ARGENX SE stock be interpreted?

Volatility is around 34,68%.

Ad
Chaque matin
Les signaux techniques du marché,
avant l'ouverture.
CAC 40 · SBF 120 · Signaux · Analystes
🤖
Édition du jour — avant bourse
CAC 40
7 702
-0,87%
SBF 120
5 827
-0,87%
📈 Signaux haussiers
+5,2%
+1,8%
+0,9%
📉 Signaux baissiers
-14%
-5,7%
🔄 Avis analystes
▲ 35 €
▼ 80 €
Inscrivez-vous pour tout voir →
Avant 9h chaque matin
Données Euronext
Analyse automatique IA
BOURSE · Chaque matin
La synthèse bourse,
avant l'ouverture.
Notre moteur analyse chaque nuit le CAC 40 et le SBF 120. Ce qui mérite attention remonte directement dans votre boîte mail. Gratuit.
Avant 9h00 1000+ inscrits 100% gratuit